110 related articles for article (PubMed ID: 20883323)
1. The proportion of CD3- CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES).
Helbig G; Wichary R; Razny M; Rodzaj M; Wozniczka K; Dziaczkowska-Suszek J; Kyrcz-Krzemien S
Scand J Immunol; 2010 Oct; 72(4):372-3. PubMed ID: 20883323
[No Abstract] [Full Text] [Related]
2. Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome.
Tabata R; Tabata C; Katashima Y; Yasumizu R
Int Immunopharmacol; 2013 Aug; 16(4):488-91. PubMed ID: 23669338
[TBL] [Abstract][Full Text] [Related]
3. 6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome.
Ravoet M; Sibille C; Roufosse F; Duvillier H; Sotiriou C; Schandené L; Martiat P; Goldman M; Willard-Gallo KE
Haematologica; 2005 Jun; 90(6):753-65. PubMed ID: 15951288
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
5. The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.
Lefèvre G; Copin MC; Staumont-Sallé D; Avenel-Audran M; Aubert H; Taieb A; Salles G; Maisonneuve H; Ghomari K; Ackerman F; Legrand F; Baruchel A; Launay D; Terriou L; Leclech C; Khouatra C; Morati-Hafsaoui C; Labalette M; Borie R; Cotton F; Gouellec NL; Morschhauser F; Trauet J; Roche-Lestienne C; Capron M; Hatron PY; Prin L; Kahn JE;
Medicine (Baltimore); 2014 Oct; 93(17):255-266. PubMed ID: 25398061
[TBL] [Abstract][Full Text] [Related]
6. JAK inhibition for CD3
Faguer S; Groh M; Vergez F; Hunault-Berger M; Duployez N; Renaudineau Y; Paul C; Lefevre G; Kahn JE
Clin Immunol; 2023 Jun; 251():109275. PubMed ID: 36870379
[TBL] [Abstract][Full Text] [Related]
7. [Endomyocardial disease as the first manifestation of hypereosinophilic syndrome].
Poreba M; Rostoff P; Konduracka E; Pikul P; Rucińska M; Pasowicz M; Piwowarska W
Kardiol Pol; 2010 Apr; 68(4):440-5. PubMed ID: 20425707
[TBL] [Abstract][Full Text] [Related]
8. Defective CD3gamma gene transcription is associated with NFATc2 overexpression in the lymphocytic variant of hypereosinophilic syndrome.
Willard-Gallo KE; Badran BM; Ravoet M; Zerghe A; Burny A; Martiat P; Goldman M; Roufosse F; Sibille C
Exp Hematol; 2005 Oct; 33(10):1147-59. PubMed ID: 16219537
[TBL] [Abstract][Full Text] [Related]
9. [Horton's disease and hypereosinophilic syndrome: a non-fortuitous association].
Liozon E; Soria P; Gissot V; Loustaud V; Jauberteau MO; Vidal E
Ann Med Interne (Paris); 2000 Nov; 151(7):603-605. PubMed ID: 11139663
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways.
Ravoet M; Sibille C; Gu C; Libin M; Haibe-Kains B; Sotiriou C; Goldman M; Roufosse F; Willard-Gallo K
Blood; 2009 Oct; 114(14):2969-83. PubMed ID: 19608752
[TBL] [Abstract][Full Text] [Related]
11. CD3
Carpentier C; Schandené L; Dewispelaere L; Heimann P; Cogan E; Roufosse F
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2426-2439.e7. PubMed ID: 33545400
[TBL] [Abstract][Full Text] [Related]
12. Cyclical hypereosinophilia with skin manifestations and a clonal T cell population.
González Delgado P; de la Sen Fernández ML; Soriano Gomis V; Pérez Crespo M; Muñoz Ruiz C; Hernández Niveiro E
J Investig Allergol Clin Immunol; 2008; 18(5):401-3. PubMed ID: 18973106
[TBL] [Abstract][Full Text] [Related]
13. Romidepsin is an effective and well-tolerated therapy in CD3
Baulier G; Asli B; Galicier L; Fieschi C; Brice P; Malphettes M
J Allergy Clin Immunol Pract; 2019; 7(8):2885-2887.e1. PubMed ID: 31078759
[No Abstract] [Full Text] [Related]
14. More than 13 years of hypereosinophila associated with clonal CD3-CD4+ lymphocytosis of TH2/TH0 type.
Sugimoto K; Tamayose K; Sasaki M; Danbara T; Aikawa Y; Ogawa H; Sato N; Tashiro E; Oshimi K
Int J Hematol; 2002 Apr; 75(3):281-4. PubMed ID: 11999356
[TBL] [Abstract][Full Text] [Related]
15. Lymphocytic variant hypereosinophilic syndromes.
Roufosse F; Cogan E; Goldman M
Immunol Allergy Clin North Am; 2007 Aug; 27(3):389-413. PubMed ID: 17868856
[TBL] [Abstract][Full Text] [Related]
16. [Idiopathic hypereosinophilic syndrome: from the clinic to the laboratory, from the laboratory to the clinic].
Roufosse F; Cogan E
Rev Med Brux; 2001 Apr; 22(2):A113-5. PubMed ID: 11388032
[No Abstract] [Full Text] [Related]
17. Superficial venous thrombophlebitis as the initial manifestation of hypereosinophilic syndrome: study of the first 3 cases.
Terrier B; Piette AM; Kerob D; Cordoliani F; Tancrède E; Hamidou L; Lebbé C; Blétry O; Kahn JE
Arch Dermatol; 2006 Dec; 142(12):1606-10. PubMed ID: 17178987
[TBL] [Abstract][Full Text] [Related]
18. Differential changes in CD4+ and CD8+ effector and regulatory T lymphocyte subsets in the testis of rats undergoing autoimmune orchitis.
Jacobo P; Guazzone VA; Jarazo-Dietrich S; Theas MS; Lustig L
J Reprod Immunol; 2009 Jul; 81(1):44-54. PubMed ID: 19520436
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of hypereosinophilic syndrome with cyclosporine.
Donald CE; Kahn MJ
Am J Med Sci; 2009 Jan; 337(1):65-6. PubMed ID: 19002011
[TBL] [Abstract][Full Text] [Related]
20. All systems red.
Karmacharya P; Donato AA; Aryal MR; Pathak R; Goonewardene M; Valent P
Am J Hematol; 2015 Apr; 90(4):356-60. PubMed ID: 25294166
[No Abstract] [Full Text] [Related]
[Next] [New Search]
